Malignant hyperthermia.
The true incidence of malignant hyperthermia is unknown, but the frequency has been estimated as high as 1/14,000 anesthetic events. Review of the literature reports mortality rates up to 70%. Without prompt medical intervention, it is a uniformly fatal disease. Thus, it behooves the physician to have an awareness of the syndrome and its features, so that early recognition and adequate treatment take place. This paper presents a review of the literature on the occurrence, pathology, symptoms and treatment of malignant hyperthermia.
D000138:Acidosis / Q000188:drug therapy / Q000209:etiology; D001639:Bicarbonates / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D003402:Creatine Kinase; D003620:Dantrolene / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005334:Fever / Q000150:complications; D006801:Humans; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D009127:Muscle Rigidity / Q000139:chemically induced; D009129:Muscle Tonus / Q000187:drug effects; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D017693:Sodium Bicarbonate; D013390:Succinylcholine / Q000009:adverse effects; D014883:Water-Electrolyte Imbalance / Q000188:drug therapy
D001639:Bicarbonates; D004232:Diuretics; D017693:Sodium Bicarbonate; D003402:Creatine Kinase; D003620:Dantrolene; D013390:Succinylcholine; D002118:Calcium